Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)

作者：Deng, Jiaojiao; Hua, Lingyang; Bian, Liuguan; Chen, Hong; Chen, Ligang; Cheng, Hongwei; Dou, Changwu; Geng, Dangmurenjiapu; Hong, Tao; Ji, Hongming; Jiang, Yugang; Lan, Qing; Li, Gang; Liu, Zhixiong; Qi, Songtao; Qu, Yan; Shi, Songsheng; Sun, Xiaochuan; Wang, Haijun; You, Yongping; Yu, Hualin; Yue, Shuyuan; Zhang, Jianming; Zhang, Xiaohua; Wang, Shuo; Mao, Ying; Zhong, Ping^*; Gong, Ye^*

来源：Chinese Medical Journal, 2022, 135(16): 1894-1912.

DOI：10.1097/CM9.0000000000002391

• Clinical diagnosis
• Expert consensus
• Meningioma
• Molecular subtyping
• Therapeutic treatment

Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.

• 单位
  苏州大学; 1; 南方医科大学; 南昌大学; 山东大学; 上海交通大学; 中山大学; 安徽医科大学; 中国人民解放军第四军医大学; 内蒙古医学院; y; 复旦大学; 浙江大学